Contrasting Adverum Biotechnologies

Contrasting Adverum Biotechnologies


Adverum Biotechnologies and Seattle Genetics are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Adverum Biotechnologies has a beta of 3.63, meaning that its share price is 263% more volatile than the S&P 500.



from Biotech News